Citation Impact
Citing Papers
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
The Systemic Amyloidoses
1997 Standout
Burden of liver diseases in the world
2018 Standout
Development of vaccines and antivirals for combating viral pandemics
2020 StandoutNobel
Familial Mediterranean Fever
2012 Standout
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Sexually Transmitted Infections Treatment Guidelines, 2021
2021 Standout
Colchicine Therapy for Familial Mediterranean Fever
1974
An overview of the role of nucleosides in chemotherapy
1985 StandoutNobel
Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach
2020 Standout
An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study
2020 Standout
Prophylactic Colchicine Therapy in Familial Mediterranean Fever
1974
Approved Antiviral Drugs over the Past 50 Years
2016
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
2020 Standout
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
2018
Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2′-O-ribose methyltransferase
2020
Antiviral agents as adjuncts in cancer chemotherapy
1980
Works of Will Garner being referenced
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
2017
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial
2014
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults
2016
Inhibition of DNA polymerases from RNA tumor viruses by tilorone and congeners: Site of action
1974
Colchicine for Familial Mediterranean Fever (Periodic Peritonitis) — Concl.
1974